FDA Panel Backs Donanemab: New Hope for Early Alzheimer’s Treatment

Image caption: By the end of the trial, 60% of patients were able to effectively stop Donanemab treatment. Image credit: Neuroscience News. Article by Neuroscience News Communications. Neuroscience News – June 10, 2024.

Summary: An independent panel has recommended that Eli Lilly’s Alzheimer’s drug, Donanemab, be approved by the FDA. The drug has shown promise in slowing early-stage Alzheimer’s despite risks like brain swelling. This recommendation follows a prior FDA rejection due to insufficient data. If approved, Donanemab could revolutionize Alzheimer’s treatment, offering new hope for patients and their families. […]

Click here to view original web page at neurosciencenews.com

Related articles:

FDA panel makes the call on much-anticipated Alzheimer’s drug donanemab – USA Today

FDA Panel Unanimously Recommends Eli Lilly’s Alzheimer’s Drug – Forbes

FDA advisors strongly back new Alzheimer’s drug, despite risks and limitations – NPR